Novo Nordisk inks $2.1B oral obesity drug deal
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.
Related Stories
Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 7 months
Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 7 months
Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 4 months
JP Morgan Healthcare Conference 2026: Pharma, AI, and Innovation Highlights / 5 months
Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 6 months
Novo launches high‑dose Wegovy in US at $399 for self‑pay patients / 3 months
Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Adolescent Health, Autism, Drug Development, Health Disparities and look for the RSS link.
StackHealth Time Machine